Business
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n - Forms new subsidiary, 3CL Pharma, focused on the development and commercialization of 3CL protease-related products including Tollovir™, Tollovid®, Tollovid Daily™ and TolloTest™ for COVID-19 - - Positions Todos Medical as the leader of oral antivirals for hospitalized COVID-19 patients to speed time to discharge; key data from the Tollovir™ Phase 2 clinical trial showed a reduction of 7.2 days of hospitalization - - Development plan includes Tollovir EUA submissions Worldwide and preparations for Phase 2b/3 pivotal, and Tollovid initial real-world study to investigate conversion from dietary supplement to over-the-counter drug for long COVID and pediatrics uses - NEW YORK, NY and Tel Aviv, ISRAEL, March 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has completed the acquisition of all 3CL protease biology-related assets and formed a majority-owned subsidiary called 3CL Pharma Ltd. (“3CL Pharma”). 3CL Pharma will focus on developing therapeutics, diagnostics and dietary supplements based on 3CL protease (3CLpro, Main Protease, Mpro, Nsp5) biology related work of Dr. Dorit Arad, who joins Todos Medical as the newly appointed Chief Scientific Officer. This acquisition solidifies Todos Medical’s position as a key player in the development and commercialization of 3CL protease-related products. These assets currently include: Tollovir®, a botanical drug candidate for the treatment of hospitalized patients with COVID-19 and other nidovirus coronaviruses; TolloTest™, a diagnostic testing platform to identify the presence of the 3CL protease related to SARS-CoV-2; and Tollovid® & Tollovid Daily™, 3CL protease inhibitor dietary supplements that support and maintain healthy immune function. Additionally, the assets include new intellectual property that covers follow-on products based on Tollovir, including new chemical entity (NCE) therapeutic candidates. Dr. Dorit Arad, PhD, will serve as Chief Technology Officer of 3CL Pharma. Dr. Arad brings extensive experience and access to discoveries related to the development and commercialization of new chemical entities targeting the 3CL protease. “We are very excited to close the ag...